REGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

788.250

Open

781.050

VWAP

779.41

Vol

202.89K

Mkt Cap

82.63B

Low

774.780

Amount

158.13M

EV/EBITDA(TTM)

17.37

Total Shares

105.72M

76.73B

EV/OCF(TTM)

15.41

P/S(TTM)

5.92

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Events Timeline

(ET)

2026-03-09

07:10:00

Regeneron Partners with Hansoh on Obesity Drug Development

2026-02-27 (ET)

2026-02-27

07:10:00

Regeneron and Sanofi's Dupixent Receives Positive EMA Opinion

2026-02-24 (ET)

2026-02-24

09:40:00

Regeneron and Sanofi's Dupixent Approved by FDA for Allergic Fungal Rhinosinusitis

2026-02-19 (ET)

2026-02-19

07:20:00

Regeneron Pharmaceuticals' Garetosmab Accepted for FDA Priority Review

News

9.0

03-09Newsfilter

PinnedRegeneron's Olatorepatide Trial Shows Significant Weight Loss Results

9.0

03-09NASDAQ.COM

Regeneron's Obesity Drug Trial Shows Positive Results

9.0

03-09seekingalpha

Regeneron and Hansoh Pharma Report Positive Phase 3 Results for Obesity Drug

8.5

03-08NASDAQ.COM

Regeneron and Roche Compete in Weight Loss Drug Market

7.5

03-08Fool

Pharmaceutical Companies' Potential in Weight Loss Market

7.0

03-06CNBC

FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism

22 Analyst Rating

Wall Street analysts forecast REGN stock price to rise

16 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Barclays

Overweight

initiated

$923

AI Analysis

2026-03-06

New

Reason

Barclays

Price Target

$923

AI Analysis

2026-03-06

New

initiated

Overweight

Reason

Barclays initiated coverage of Regeneron with an Overweight rating and $923 price target. The shares are "fundamentally mispricing" the company's profits from Dupixent over the near- and medium-term, the analyst tells investors in a research note. Barclays also believes Regeneron's pipeline opportunities are undervalued at current share levels, particularly Lynozyfic. The firm views Dupixent indication expansion as an "underappreciated tailwind" for the company.

RBC Capital

Brian Abrahams

Sector Perform

maintain

$745 -> $765

2026-03-02

Reason

RBC Capital

Brian Abrahams

Price Target

$745 -> $765

2026-03-02

maintain

Sector Perform

Reason

RBC Capital analyst Brian Abrahams raised the firm's price target on Regeneron to $765 from $745 and keeps a Sector Perform rating on the shares. The firm is positive on the company's R&D engine and sees the underappreciated medium-term growth from dupi, pipeline, and the Sanofi (SNY) repayment, the analyst tells investors in a research note. RBC adds however that shares may continue to trade at a discount, pressured by Eylea headwinds and dupi LOE uncertainty

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 17.21, compared to its 5-year average forward P/E of 16.46. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

16.46

Current PE

17.21

Overvalued PE

20.04

Undervalued PE

12.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.30

Current EV/EBITDA

10.56

Overvalued EV/EBITDA

14.19

Undervalued EV/EBITDA

8.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.77

Current PS

5.37

Overvalued PS

6.93

Undervalued PS

4.61

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stock to buy today

Intellectia · 20 candidates

Market Cap: >= 50.00BNet Margin: >= 15.00Pe Ttm: 10 - 25Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Anglogold Ashanti PLC

63.67B

AEM

Agnico Eagle Mines Ltd

123.28B

CNI

Canadian National Railway Co

67.41B

NEM

Newmont Corporation

138.67B

NVS

Novartis

315.82B

CSX

CSX Corp

79.31B

best stocks to buy

Intellectia · 28 candidates

Market Cap: >= 30.00BRegion: USRevenue 5yr Cagr: >= 10Pe Ttm: 12 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

META

Meta Platforms Inc

1.68T

Micron Technology Inc

439.39B

NVO

Novo Nordisk A/S

279.76B

SCHW

Charles Schwab Corp

183.27B

NEE

Nextera Energy Inc

181.23B

i want you to screen usar stock

Intellectia · 17 candidates

Net Margin: >= 15.00Revenue 5yr Cagr: >= 10Pe Ttm: 10 - 25List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Morgan Stanley

287.52B

Goldman Sachs Group Inc

278.76B

MRK

Merck & Co Inc

267.41B

SCHW

Charles Schwab Corp

183.31B

NEM

Newmont Corporation

140.53B

Chubb Ltd

118.42B

Any sector any risk

Intellectia · 39 candidates

Net Margin: >= 8.00Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 12.0%Is Index Component: GSPC

Ticker

Name

Market Cap$

Micron Technology Inc

437.95B

NEM

Newmont Corporation

129.76B

ULTA

Ulta Beauty Inc

30.32B

MPWR

Monolithic Power Systems Inc

51.50B

Goldman Sachs Group Inc

285.83B

SCHW

Charles Schwab Corp

180.87B

what us stocks should i buy

Intellectia · 44 candidates

Market Cap: >= 20.00BMarket Cap Category: largeNet Margin: >= 0.00Pe Ttm: 8 - 45List Exchange: XNASIs Index Component: NDXMonthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

KLAC

KLA Corp

199.72B

AMGN

Amgen Inc

185.02B

TXN

Texas Instruments Inc

176.65B

BKNG

Booking Holdings Inc

166.44B

GILD

Gilead Sciences Inc

160.18B

PDD

PDD Holdings Inc

150.37B

financial metrics alone

Intellectia · 32 candidates

Revenue Ttm: >= 25Price: >= $15.00Eps Ttm: >= 25Return On Equity: >= 15.0%

Ticker

Name

Market Cap$

KSPI

Kaspi.kz AO

14.51B

NVR

NVR Inc

22.14B

PDD

PDD Holdings Inc

150.37B

FUTU

Futu Holdings Ltd

23.11B

COKE

Coca-Cola Consolidated Inc

10.26B

RGS

Regis Corp

59.16M

was soll ich heute kaufen.

Intellectia · 12 candidates

Market Cap: >= 2.00BRegion: USThemes: BiotechMarket Cap Category: mid, largeRevenue 5yr Cagr: >= 0Weekly Average Turnover: >= 1,000,000List Exchange: XNYS, XNAS, XASEIs Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

ILMN

Illumina Inc

23.30B

list of biotech stock

Intellectia · 11 candidates

Market Cap: >= 1000.00MThemes: BiotechBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

Whales Holding REGN

Freemont Capital Pte. Ltd.

Polar Capital Holdings Plc

ARS Investment Partners, LLC

Two Sigma Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 775.205 USD — it has decreased -0.82

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

What is the price predicton of REGN Stock?

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

Regeneron Pharmaceuticals Inc revenue for the last quarter amounts to 3.88B USD, increased 2.51

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

Regeneron Pharmaceuticals Inc. EPS for the last quarter amounts to 7.84 USD, decreased -2.97

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

Regeneron Pharmaceuticals Inc (REGN) has 15410 emplpoyees as of March 10 2026.

What is Regeneron Pharmaceuticals Inc (REGN) market cap?

Today REGN has the market capitalization of 82.63B USD.

REGN Overview

REGN Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding REGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

What is the price predicton of REGN Stock?

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

What is Regeneron Pharmaceuticals Inc (REGN) market cap?